Literature DB >> 11696534

Small heterodimer partner, an orphan nuclear receptor, augments peroxisome proliferator-activated receptor gamma transactivation.

Hitoshi Nishizawa1, Kazuya Yamagata, Iichiro Shimomura, Masahiko Takahashi, Hiroshi Kuriyama, Ken Kishida, Kikuko Hotta, Hiroyuki Nagaretani, Norikazu Maeda, Morihiro Matsuda, Shinji Kihara, Tadashi Nakamura, Hidekazu Nishigori, Hideaki Tomura, David D Moore, Jun Takeda, Tohru Funahashi, Yuji Matsuzawa.   

Abstract

Small heterodimer partner (SHP, NR0B2) is an atypical orphan nuclear receptor that inhibits transcriptional activation by several other nuclear receptors. We recently reported that mutations in the SHP gene are associated with insulin resistance. In the present study, we demonstrated that the SHP gene is expressed in adipose tissues. A reporter gene assay showed that a gene product of SHP increased the transcriptional activation of peroxisome proliferator-activated receptor (PPAR) gamma. SHP-mediated activation of PPARgamma was observed both in the presence and absence of the ligand of PPARgamma. Immunoprecipitation and glutathione S-transferase pull-down assay showed that SHP directly bound to PPARgamma and competed with nuclear receptor corepressor for binding to PPARgamma. Serial deletion studies indicated that the C terminus of SHP is important for PPARgamma activation. Mutant SHP proteins, which are found in naturally occurring mutation, showed less enhancing activity for PPARgamma than wild-type SHP. Our results suggest that SHP may act as an endogenous enhancer of PPARgamma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11696534     DOI: 10.1074/jbc.M104301200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Effects of FXR in foam-cell formation and atherosclerosis development.

Authors:  Grace L Guo; Silvia Santamarina-Fojo; Taro E Akiyama; Marcelo J A Amar; Beverly J Paigen; Bryan Brewer; Frank J Gonzalez
Journal:  Biochim Biophys Acta       Date:  2006-10-14

Review 2.  Role of nuclear receptor SHP in metabolism and cancer.

Authors:  Yuxia Zhang; Curt H Hagedorn; Li Wang
Journal:  Biochim Biophys Acta       Date:  2010-10-20

Review 3.  Cell signaling and nuclear receptors: new opportunities for molecular pharmaceuticals in liver disease.

Authors:  Jeff L Staudinger; Kristin Lichti
Journal:  Mol Pharm       Date:  2007-12-27       Impact factor: 4.939

4.  Gene expression profiling reveals a diverse array of pathways inhibited by nuclear receptor SHP during adipogenesis.

Authors:  Guisheng Song; Kyungtae Park; Li Wang
Journal:  Int J Clin Exp Pathol       Date:  2008-11-03

Review 5.  The orphan nuclear receptors at their 25-year reunion.

Authors:  Shannon E Mullican; Joanna R Dispirito; Mitchell A Lazar
Journal:  J Mol Endocrinol       Date:  2013-11-26       Impact factor: 5.098

Review 6.  microRNAs as regulators of adipogenic differentiation of mesenchymal stem cells.

Authors:  Dana Hamam; Dalia Ali; Moustapha Kassem; Abdullah Aldahmash; Nehad M Alajez
Journal:  Stem Cells Dev       Date:  2014-12-31       Impact factor: 3.272

7.  Adamantyl-substituted retinoid-related molecules bind small heterodimer partner and modulate the Sin3A repressor.

Authors:  Lulu Farhana; Marcia I Dawson; Mark Leid; Li Wang; David D Moore; Gang Liu; Zeben Xia; Joseph A Fontana
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

Review 8.  PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Nucl Recept Signal       Date:  2010-04-16

9.  Differential inhibition of nuclear hormone receptor-dependent hepatitis B virus replication by the small heterodimer partner.

Authors:  Claudia E Oropeza; Lie Li; Alan McLachlan
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

10.  Regulation of bile acid and cholesterol metabolism by PPARs.

Authors:  Tiangang Li; John Y L Chiang
Journal:  PPAR Res       Date:  2009-07-14       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.